Book a demo
Capital & FinanceEvent: September 3, 2026

Lonza is investing $125M into its GIVE program to replace massive factories with automated, point-of-care devices.

Published

Signal category

Capital & Finance

Quote

ARPA-H is investing $125M into its GIVE program.

Peng Wang, Ph.D.|Lonza team

Company

Lonza

Making the Medicines of Tomorrow

Industry
Pharmaceutical Manufacturing
Location
Basel, CH
Company size
19,351 employees

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Founded 1897

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.